Emtricitabine – Antiviral HIV Therapy

Emtricitabine is a potent nucleoside reverse transcriptase inhibitor (NRTI), a cytidine analogue used for the treatment of HIV infection and Hepatitis B virus. The drug is a cornerstone component of modern antiretroviral therapy.

The mechanism of action of emtricitabine involves its intracellular phosphorylation into its active triphosphate form. In this state, it competes with the natural substrate (deoxycytidine 5'-triphosphate) and is incorporated into the developing viral DNA chain. This results in immediate chain termination, as the lack of the necessary chemical bond blocks further replication of the virus's genetic material. Due to its high specificity for viral enzymes, the drug effectively suppresses the replication of HIV-1, HIV-2, and Hepatitis B virus (HBV), while maintaining low cytotoxicity.

The drug is characterized by a long intracellular half-life, allowing for once-daily dosing. Emtricitabine is frequently used as part of fixed-dose combinations (e.g., with tenofovir).

Wikipedia page

Indications

Emtricitabine is used for the treatment of adult and pediatric patients in the following cases:

HIV-1 Infection: as part of combination antiretroviral therapy to control viral load.
Pre-exposure Prophylaxis (PrEP): in combination with other agents to reduce the risk of HIV-1 acquisition in high-risk individuals.
Chronic Hepatitis B: as an additional benefit when treating co-infected HIV patients (the drug is active against HBV).

Dosage and administration

Emtricitabine dosing is standardized but requires adjustment in patients with impaired renal function.

Standard Adult Dose: 200 mg once daily.
Administration Rules: capsules are taken orally regardless of food intake.
Pediatric Dosage: calculated individually based on body weight (usually 6 mg/kg in solution or capsule form).
Renal Impairment: for creatinine clearance less than 50 mL/min, the dosing interval must be increased or the dose reduced.
Special Note: the drug should not be abruptly discontinued in patients co-infected with Hepatitis B due to the risk of severe disease flare-ups.

The use of emtricitabine is restricted in the following situations:

Hypersensitivity: allergic reactions to emtricitabine or any components of the drug.
Renal Impairment: end-stage renal disease (where dose adjustment is not possible).
Breastfeeding: women with HIV are advised not to breastfeed to avoid transmitting the virus to the infant.
Infants: under 4 months of age (due to insufficient safety data).

Emtricitabine is generally well-tolerated, though the following side effects may occur:

Gastrointestinal: diarrhea, nausea, vomiting, and abdominal pain.
Skin Reactions: skin hyperpigmentation (primarily on palms and soles), rash, and itching.
Nervous System: headache, dizziness, insomnia, or abnormal dreams.
Laboratory Parameters: elevated levels of creatine kinase, AST, ALT, and bilirubin.
Metabolic: risk of lactic acidosis and severe hepatomegaly with steatosis (rare but serious).

Frequently Asked Questions

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI). It works by blocking the reverse transcriptase enzyme, which the human immunodeficiency virus (HIV) needs to replicate its genetic material. This halts the viral multiplication process and reduces the viral load in the body.

No, for the treatment of HIV infection, emtricitabine is always used in combination with other antiretroviral agents. This is essential to prevent the virus from developing drug resistance. However, it is frequently included in "fixed-dose combination" tablets taken once daily.

Emtricitabine (typically paired with tenofovir) is approved for use as pre-exposure prophylaxis (PrEP). When taken consistently by HIV-negative individuals at high risk, the active substance creates a barrier that significantly reduces the likelihood of the virus establishing an infection if exposure occurs.

Emtricitabine also has activity against the Hepatitis B virus (HBV). If a patient co-infected with HIV and HBV abruptly stops taking the medication, it can lead to a severe flare-up of hepatitis. Testing for HBV is mandatory before starting or stopping therapy to ensure liver safety.

Emtricitabine is generally well-tolerated. The most frequent side effects include headache, diarrhea, and nausea. A rare but specific side effect is skin hyperpigmentation (darkening), typically on the palms or soles of the feet, which usually does not require discontinuation of treatment.